mp.weixin.qq.com·· 7 hours agoScore70
OptiTROP-Lung04 Final OS Analysis to Report at ESMO 2026 in EGFR-TKI-Resistant NSCLC
In brief
Experts review survival data for sacituzumab tirumotecan in EGFR-TKI-resistant NSCLC. The final overall survival analysis of OptiTROP-Lung04 will be presented at ESMO 2026.
Source: mp.weixin.qq.com · mp.weixin.qq.com